[1]林燕玲,王 瑛,张 敏,等.上皮性卵巢癌组织中miR-506-3p及miR-532-5p的表达与临床病理特征及预后的相关研究[J].现代检验医学杂志,2022,37(03):83-86.[doi:10.3969/j.issn.1671-7414.2022.03.017]
 LIN Yan-ling,WANG Ying,ZHANG Min,et al.Correlation between the Expression of miR-506-3p and miR-532-5p and Clinicopathological Features and Prognosis in Epithelial Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):83-86.[doi:10.3969/j.issn.1671-7414.2022.03.017]
点击复制

上皮性卵巢癌组织中miR-506-3p及miR-532-5p的表达与临床病理特征及预后的相关研究()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
83-86
栏目:
论 著
出版日期:
2022-05-15

文章信息/Info

Title:
Correlation between the Expression of miR-506-3p and miR-532-5p and Clinicopathological Features and Prognosis in Epithelial Ovarian Cancer
文章编号:
1671-7414(2022)03-083-04
作者:
林燕玲王 瑛张 敏康 灵邢维珍黎先萍
(上海儿童医学中心三亚市妇女儿童医院,海南三亚 572000)
Author(s):
LIN Yan-ling WANG Ying ZHANG Min KANG Ling XING Wei-zhen LI Xian-ping
(Sanya Women and Children’s Hospital Managed by Shanghai Children’s Medical Center, Hainan Sanya 572000,China)
关键词:
上皮性卵巢癌微小核糖核酸-506-3p微小核糖核酸-532-5p
分类号:
R737.31;R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.017
文献标志码:
A
摘要:
目的 探讨 miR-506-3p及 miR-532-5p在上皮性卵巢癌( epithelial ovarian cancer,EOC)组织中的表达及其对预后预测的意义。方法 选取 2017年 1月~ 2019年 12月三亚市妇女儿童医院和三亚中心医院收治的 118例 EOC患者。检测 EOC组织及正常组织中 miR-506-3p及 miR-532-5p表达水平。应用单因素及多因素 COX回归模型分析 EOC患者预后不良的危险因素。结果 EOC组织 miR-506-3p(0.31±0.05)及 miR-532-5p(0.24±0.03)表达水平低于正常组织( 1.16±0.42,1.48±0.51),差异有统计学意义( t=13.582,16.217,均 P<0.001)。Kaplan-Meier生存分析显示, miR-506-3p及 miR-532-5p低表达与 EOC患者生存期短有关( P<0.001)。多因素分析显示,淋巴结转移 [HR(95%CI) =1.840(1.137~ 4.105)],腹膜转移 [HR(95%CI)=2.974(2.106~ 6.113)],miR-506-3p< 0.45[HR(95%CI)=1.902(1.217~ 4.533)]及 miR-532-5p< 0.32[HR(95%CI)=2.506(1.582~ 4.905)]是影响 EOC患者预后不良的独立危险因素(均 P<0.05)。结论  miR-506-3p及 miR-532-5p在 EOC组织中明显下调,其低表达的 EOC患者生存期较短,对 EOC患者预后预测具有较好的价值。
Abstract:
Objective To investigate the expression of miR-506-3p and miR-532-5p in epithelial ovarian cancer (EOC) and its prognostic significance. Methods The 118 patients with EOC admitted to Sanya Woman and Children’s Hospital and Sanya Central Hospital from January 2017 to December 2019 were selected. The expression levels of miR-506-3p and miR- 532-5p in EOC and normal tissues were detected. Univariate and multivariate COX regression models were used to analyze the risk factors of poor prognosis in EOC patients. Results The expression level of miR-506-3p (0.31±0.05 ) and miR-532- 5p (0.24±0.03 ) in EOC were lower than that in normal tissues(1.16±0.42,1.48±0.51 ),the differences were statistically significant (t=13.582, 16.217, all P<0.001). Kaplan-Meier survival analysis showed that low expression of miR-506-3p and miR- 532-5p were associated with short survival of EOC patients (P<0.001). Multivariate Cox regression analysis showed that lymph node metastasis[HR(95%CI)=1.840(1.137 ~ 4.105)], peritoneal metastasis[HR(95%CI)=2.974(2.106 ~ 6.113)], miR-506-3p<0.45 [HR(95%CI)=1.902(1.217 ~ 4.533)]and miR-532-5p<0.32[HR(95%CI)=2.506(1.582 ~ 4.905)] were independent risk factors for poor prognosis of EOC patients (all P<0.05). Conclusion miR-506-3p and miR-532-5p were significantly down-regulated in EOC tissues, and the survival time of EOC patients with low expression of miR-506-3p was shorter, which had a good value for predicting the prognosis of EOC patients.

参考文献/References:

[1] WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017, 41(5): 3-14.
[2] PISZCZAN S, DESALEGN D, PETROS H, et al. Clinical characteristics and survival of patients with malignant ovarian tumors in Addis Ababa, Ethiopia[J]. The Oncologist, 2019, 24(6): e303-e311.
[3] PARIZADEH S M, JAFARZADEH-ESFEHANI R, GHANDEHARI M, et al. Circulating and tissue microRNAs as biomarkers for ovarian cancer prognosis[J]. Current Drug Targets, 2019, 20(14): 1447-1460.
[4] DEB B, UDDIN A, CHAKRABORTY S. MiRNAs and ovarian cancer: an overview[J]. Journal of Cellular Physiology, 2018, 233(5): 3846-3854.
[5] NAM E J, KIM S, LEE T S, et al. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue[J]. Oncotarget, 2016, 7(43): 70524-70534.
[6] ZHOU Yuanyuan, ZHENG Xia, LU Jiaojiao, et al. Ginsenoside 20(S)-Rg3 inhibits the warburg effect via modulating DNMT3A/ MiR-532-3p/HK2 pathway in ovarian cancer cells[J]. Cellular Physiology and Biochemistry, 2018, 45(6): 2548-2559.
[7] JAVADI S, GANESHAN D M, QAYYUM A, et al. Ovarian cancer, the revised FIGO staging system, and the role of imaging[J]. American Journal of Roentgenology, 2016, 206(6): 1351-1360.
[8] OLIVEIRA D N P, CARLSEN A L, HEEGAARD N H H, et al. Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass[J]. PLoS One, 2019, 14(11): e0225249.
[9] Z?VESK? L, JAND?KOV? E, WEINBERGER V, et al. Ovarian cancer: Differentially expressed microRNAs in tumor tissue and cell-free ascitic fluid as potential novel biomarkers[J]. Cancer Investigation, 2019, 37(9): 440-452.
[10] ZHAO Laigang, WANG Jiao, LI Jin, et al. MiR-744-5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer[J]. The Kaohsiung Journal of Medical Sciences, 2020, 36(10): 799-807.
[11] WANG Yuan, LEI Xia, GAO Chengying, et al. MiR- 506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6[J]. Journal of Biosciences, 2019, 44(6): 126.
[12] WANG Fan, CHANG J T H, KAO C J, et al. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro[J]. Molecular Cancer Therapeutics, 2016, 15(5): 1123-1131.
[13] SAMUEL P, CARTER D R. The diagnostic and prognostic potential of microRNAs in epithelial ovarian carcinoma[J]. Molecular Diagnosis & Therapy, 2017, 21(1): 59-73.
[14] XIA X Y, YU Y J, YE F, et al. MicroRNA-506-3p inhibits proliferation and promotes apoptosis in ovarian cancer cell via targeting SIRT1/AKT/FOXO3a signaling pathway[J]. Neoplasma, 2020, 67(2): 344-353.
[15] WEI H, TANG Q L, ZHANG K, et al. MiR-532-5p is a prognostic marker and suppresses cells proliferation and invasion by targeting TWIST1 in epithelial ovarian cancer[J]. European Review for Medical and Pharmacological Sciences, 2018, 22(18): 5842-5850.
[16] ZHANG Ruitao, SHI Huirong, REN Fang, et al. Down-regulation of miR-338-3p and Up-regulation of MACC1 indicated poor prognosis of epithelial ovarian cancer patients[J]. Journal of Cancer, 2019, 10(6): 1385-1392.

相似文献/References:

[1]邓森灵,兰代群,曹雅文,等.上皮性卵巢癌患者血清miR-362 和miR-485 的表达水平及其与预后的相关性研究[J].现代检验医学杂志,2022,37(04):35.[doi:10.3969/j.issn.1671-7414.2022.04.007]
 DENG Sen-ling,LAN Dai-qun,CAO Ya-wen,et al.Expression of miR-362 and miR -485 in Serum of Patients with Epithelial Ovarian Cancer and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(03):35.[doi:10.3969/j.issn.1671-7414.2022.04.007]
[2]李 苗,龚 姗,金海红,等.上皮性卵巢癌组织CDCA7 表达水平及其与患者预后的相关性研究[J].现代检验医学杂志,2023,38(02):118.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]
 LI Miao,GONG Shan,JIN Hai-hong,et al.Expression Level of CDCA7 in Epithelial Ovarian Cancer Tissues and Its Correlation with Prognosis of Patients[J].Journal of Modern Laboratory Medicine,2023,38(03):118.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]

备注/Memo

备注/Memo:
基金项目:海南省临床医学中心建设资助。
作者简介:林燕玲(1984-), 女,本科,主治医师,主要从事临床妇产科疾病研究,E-mail: lyl_841220@163.com。
更新日期/Last Update: 1900-01-01